

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Leukemia	Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa; HSPA5; GRP78)	<p><i>In vitro</i> and mouse studies suggest inhibiting GRP78 could help treat leukemia. In a <i>Pten</i> (<i>Mmac1; Tep1</i>)<sup>-/-</sup> mouse model of leukemia, heterozygous knockout of Grp78 suppressed myeloproliferative disease and prevented leukemic blast cell proliferation compared with no Grp78 knockout. Next steps could include testing GRP78 inhibition in additional leukemia models.</p> <p>Patrys Ltd.'s PAT-SM6, an antibody against GRP78, is in Phase I testing to treat melanoma.</p> <p><b>SciBX 4(40); doi:10.1038/scibx.2011.1111</b>  <b>Published online Oct. 13, 2011</b></p>	Patent and licensing status unavailable	<p>Wey, S. <i>et al. Blood</i>; published online Sept. 21, 2011; doi:10.1182/blood-2011-06-357384</p> <p><b>Contact:</b> Amy S. Lee, USC Norris Comprehensive Cancer Center, Los Angeles, Calif.            e-mail: <a href="mailto:amylee@ccnt.usc.edu">amylee@ccnt.usc.edu</a></p>